Compare Abeona Therapeutics Inc (ABEO) vs Veritone Inc (VERI) Price & Performance

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

Veritone (VERI) trades at $1.36, up 3.82% on the day, but remains under significant pressure with a bearish technical signal and negative profitability. The company reported a net loss of $111.73 million in 2025, with a net income margin of -123.76%, while revenue declined slightly to $90 million in 2026. Multiple class-action lawsuits filed in July 2026 allege securities fraud related to improper revenue accounting, creating substantial legal overhangs.

The outlook is highly speculative; while the consensus price target of $5.25 implies significant upside, the stock faces severe fundamental challenges and legal risks. Investment opportunity hinges on successful business turnaround and resolution of litigation, but current financial performance and negative cash flow from operations present substantial downside risk.